Provectus Biopharmaceuticals Capital Expenditures (CapEx) Growth & History (PVCT)

Provectus Biopharmaceuticals's capital expenditures (capex) was $30,400 for fiscal 2017.

View full Provectus Biopharmaceuticals company overview

Provectus Biopharmaceuticals annual capital expenditures (capex) history

Provectus Biopharmaceuticals annual capital expenditures (capex)

Fiscal yearPeriod endedCapital expenditures (CapEx)ChangeGrowth
20172017-12-31$30,400
20152015-12-31$6,139−$64,451−91.30%
20142014-12-31$70,590$63,940+961.50%
20132013-12-31$6,650−$9,235−58.14%
20122012-12-31$15,885$9,738+158.42%
20112011-12-31$6,147
20092009-12-31$5,839

Provectus Biopharmaceuticals capital expenditures (capex) trends

Over the last five fiscal years, Provectus Biopharmaceuticals's capital expenditures (capex) increased from $15,885 to $30,400, a change of $14,515. The latest reported quarter, Q4 2012, shows $0.

About the metric

What capital expenditures (CapEx) mean

Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.

Calculation and source

SEC-reported capital expenditures

TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Provectus Biopharmaceuticals source filings ↗

Community posts

It’s quiet here.

No posts about PVCT yet. Start the conversation.

Write the first post